Signifier Medical Technologies Announces Publication of Peer-Reviewed Analysis Demonstrating Improvement in Obstructive Sleep Apnea Severity with Neuromuscular Electrical Stimulation
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical
technology company, announced that a peer-reviewed paper has recently been published in
Sleep and Breathing. The analysis, published by University of California San Diego
investigators Dr. Brandon Nokes, Professor Atul Malhotra, and other collaborators, is based
on a post-hoc analysis of 65 participants with mild obstructive sleep apnea (OSA) who
completed sleep testing before and after six weeks of genioglossus (tongue muscle)
neuromuscular electrical stimulation (NMES) with eXciteOSA.
The first of its kind, eXciteOSA is an FDA-authorized, non-invasive daytime treatment for
snoring and mild OSA. Unlike other treatment options, this does not require a nighttime
wearable, which allows patients to conveniently fit therapy into their daily routine. The therapy
works by using NMES to build endurance of the genioglossus muscle so that the tongue
doesn’t collapse into the airway during sleep. The eXciteOSA device is used for only 20
minutes per day for six weeks and then a minimum of twice per week thereafter for
maintenance.
Based on the data from the peer-reviewed analysis, the researchers observed a significant
improvement in the average apnea-hypopnea index (AHI) from 10.2 to 6.8 events/hour (33%)
among all participants, and from 10.4 to 5.0 events/hour (52%) in the responder subgroup
which represented 78% of the study sample (51 of 65). Statistically-significant improvements
in self-reported sleepiness, sleep quality, objectively measured snoring, and bed partner reported snoring were observed. Average adherence to eXciteOSA therapy was 85%.
The Sleep and Breathing article can be found here:
https://link.springer.com/article/10.1007/s11325-022-02644-9
eXciteOSA has the benefit of being a daytime-only treatment modality which confers a high
level of tolerability and patient acceptance. It alleviates the need for an in situ device during sleep and is associated with improvements in OSA severity, snoring, sleepiness, and sleep
quality. Further studies are needed to define which individuals may benefit most from the
device across the wider spectrum of OSA severity and assess long-term therapeutic
outcomes. Signifier Medical Technologies is supporting four clinical trials on these topics,
currently underway.
Signifier is a pioneer in addressing a key root cause of sleep disordered breathing. We are
focused on the development and commercialization of innovative and non-invasive solutions
that help people breathe normally and naturally all night – entirely on their own. The publication
of this study in conjunction with ongoing clinical trials represents Signifier Medical’s
commitment to research of therapies that improve population health, increase the quality of
patients’ experience, and generate healthcare savings.
-END
About Signifier Medical Technologies
Signifier is a pioneer in addressing the root causes of sleep disordered breathing. We are
focused on the development and commercialization of innovative and non-invasive solutions
that help people breathe normally and naturally all night – entirely on their own. Founded in
2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies that
improve population health, increase the quality of patients’ experience and generate
healthcare savings. Signifier has offices in London (UK), Needham (Massachusetts, USA) and
Berlin (Germany).
About eXciteOSA®
eXciteOSA is a revolutionary daytime therapy device for sleep disordered breathing. Clinically
proven to target a common root cause of OSA, eXciteOSA improves daytime sleepiness and
sleep quality. Nearly one billion adults aged 30 to 69 years globally are estimated to suffer
from OSA, which is a serious medical condition associated with health problems such as high
blood pressure and increased risks of heart attack, stroke or death.
A major underlying cause of OSA is that the upper airway muscles lack endurance during
sleep and the tongue falls back, blocking the upper airway. By using neuromuscular electrical
stimulation (NMES) to “exercise” the upper airway muscles, eXciteOSA works the intrinsic and
extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep.
Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially
available device used while awake. The full benefits of the daytime therapy are realized
without patient use during sleep.
For more information, please visit www.signifiermedical.com or www.exciteosa.com
Contacts
marketing@signifiermedical.com
+1 (844) 645 3672
References
1. Benjafield, A. V., Ayas N T, Eastwood P R et al. Estimation of the global prevalence and burden of
obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019; 7: 687-698.
2. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered
breathing and hypertension. N Engl J Med. 2000; 342:1378–1384. [PubMed: 10805822]
3. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident
coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352– 360.
[PubMed: 20625114]
4. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnoea as a risk factor for stroke and death.
N Engl J Med. 2005; 353:2034–2041. [PubMed: 16282178]
5. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea- hypopnea and incident stroke: The
Sleep Heart Health Study. Am J Respir Crit Care Med. 2010; 182:269–277. [PubMed: 20339144]
6. Peker Y, Hedner J, Norum J, et al. Increased incidence of cardiovascular disease in middle-aged men
with obstructive sleep apnoea: a 7-year follow-up. Am J Respir Crit Care Med. 2002; 166:159– 165.
[PubMed: 12119227]
7. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive
sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an
observational study. Lancet. 2005; 365:1046–1053. [PubMed: 15781100]
8. Peppard PE, Szklo-Coxe M, Hla KM, et al. Longitudinal association of sleep-related breathing disorder
and depression. Arch Intern Med. 2006; 166:1709–1715. [PubMed: 16983048]
9. Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnoea and incident diabetes: a
historical cohort study. Am J Respir Crit Care Med. 2014; 190:218–225. [PubMed: 24897551]
10. Johnson KG and Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J
of Clinical Sleep Med 2010;6(2):131-7
11. Baptista et al. Daytime Neuromuscular Electrical Therapy of Tongue Muscles in Improving Snoring.
2021
12. Kotecha. et al. A novel intraoral neuromuscular stimulation device for treating sleep-disordered
breathing. Sleep Breath. 2021.
13. Data on File. Signifier Medical Technologies
14. Davey, M. J. Epidemiological study of snoring from a random survey of 1075 participant. British Snoring
and Sleep Apnoea Association. 2002; Available at: https://britishsnoring.co.uk/pdf/epidem.pdf
